# MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease

> **NCT00374296** · PHASE2 · TERMINATED · sponsor: **Mirati Therapeutics Inc.** · enrollment: 35 (actual)

## Conditions studied

- Myelogenous Leukemia, Acute
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** MGCD0103

## Key facts

- **NCT ID:** NCT00374296
- **Lead sponsor:** Mirati Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-09
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 35 (ACTUAL)
- **Why stopped:** The Clinical Development Program for MGCD0103 is being re-evaluated
- **Last updated:** 2015-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00374296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00374296, "MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00374296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*